TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07227207: A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

Sponsor: Tessera Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 72 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,072,360

Rescue Site Savings

+$705,500

Unlock Full NCT07227207 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227207 Rescue Dossier →